ArticleArteriosclerosis, thrombosis, and vascular biology2026
Olfactomedin 2 Promotes Atherosclerosis by Eliciting Smooth Muscle Foam Cell Formation.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Olfactomedin-2 at the Crossroads of Smooth Muscle Cell Plasticity.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAtherosclerosis is a chronic vascular disease with a complex pathophysiology involving smooth muscle cell (SMC) dysfunction, and Olfm2 (olfactomedin 2) plays a role in SMC phenotype modulation. However, it is unclear if Olfm2 is involved in the development of atherosclerosis.
methodsOlfm2 global and SMC-specific knockout models were used to study its role in the development of atherosclerosis.
resultsWe found that Olfm2 was upregulated in atherosclerotic plaques of high-fat diet-fed ApoE
conclusionsOlfm2 is a novel regulator that promotes SFCF and atherosclerosis by activating NF-κB signaling. Targeting Olfm2 may be a novel potential therapeutic strategy against atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.